Baseline

(24 h urine sample)

After treatment

(urine sample collected during a 3-hour period after trial medicine intake)

Changes between Baseline and after Treatment

U-Osm (mosmol/kg)

- tolvaptan

433 ± 166

127 ± 36*

295 ± 146^#

- placebo

424 ± 174

376 ± 139

27 ± 97

U-AQP2 (ng/ml)

- tolvaptan

0.6 ± 0.3

0.2 ± 0.1*

0.5 ± 0.3^#

- placebo

0.7 ± 0.3

0.5 ± 0.3

0.0 ± 0.3

U-AQP2 (ng/mmolCr)

- tolvaptan

107.5 ± 28.7

92.3 ± 21.6*

14.6 ± 20.9^#

- placebo

108.0 ± 34.4

97.7 ± 25.9

9.1 ± 16.1^#

U-AQP2 (ng/min)

- tolvaptan

0.5 ± 0.3

0.0 ± 0.0*

0.4 ± 0.3^#

- placebo

0.5 ± 0.3

0.4 ± 0.3

0.1 ± 0.3

FE_Na (%)

- tolvaptan

0.9 ± 0.3

0.8 ± 0.4

0.1 ± 0.2

- placebo

0.8 ± 0.2

0.8 ± 0.3

0.0 ± 0.3

UO (ml/min)

- tolvaptan

1.6 ± 0.5

5.5 ± 0.4*

−3.8 ± 1.5^#

- placebo

1.5 ± 0.4

1.8 ± 0.7

−0.2 ± 0.2

Albuminexcretion rate (mg/min)

- tolvaptan

0.01 [0.00; 0.03]

0.02 [0.01; 0.04]*

−0.01 [−0.01; −0.00]^#

- placebo

0.01 [0.00; 0.02]

0.01 [0.00; 0.02]

−0.00 [−0.00; 0.01]

U-albumin (mg/mmolCr)

- tolvaptan

1.4 [0.5; 3.8]

2.5 [1.4; 4.8]*

−0.9 [−1.7; −0.1]^#

- placebo

1.3 [0.3; 2.7]

1.2 [0.4; 2.9]

−0.1 [−0.4; 0.9]